Shock and Resuscitation
The goal of fluid resuscitation is to maintain adequate perfusion. Fluid resuscitation of the wounded combatant remains a formidable challenge on the modern day battlefield. Routine resuscitation using 2 L of crystalloid through two large bore IVs is not appropriate in all situations and the vast majority of the casualties do not need any IV resuscitation prior to arrival at a forward medical treatment facility (MTF).
This chapter will briefly address shock, including recognition, classification, treatment, definition, and basic pathophysiology. Initial as well as sustained fluid resuscitation and a review of currently available fluids and potential future products will be described.
Recognition and Classification of Shock
Shock is a clinical condition marked by inadequate organ perfusion and tissue oxygenation, manifested by poor skin turgor, pallor, cool extremities, capillary refill greater than 2 seconds, anxiety/confusion/obtundation, tachycardia, weak or thready pulse, and hypotension. Lab findings include base deficit > 2, and lactic acidosis > 2.5 mmol/L.
Hypotension is a late finding in shock, after 30%–40% lost blood volume. Earlier signs are tachycardia, decreased pulse pressure, and mental status changes. Tachycardia is often not reliable; however, and relative bradycardia is common.
Table 7-1. Clinical Correlates in Hypovolemic Shock.
Cardiogenic shock: Pump failure from intrinsic cardiac failure or obstructive cardiac dysfunction from a tension pneumothorax, or cardiac tamponade with distended neck veins, or unilateral absence of breath sounds.
Distributive shock: Poor perfusion due to loss of vascular tone; neurogenic shock: bradycardia with hypotension, seen with spinal cord injury.
Treat hemorrhagic shock first.
Volume resuscitation to maintain systolic BP > 90 mm Hg.
Consider the addition of a vasopressor to address the loss in vascular tone—phenylephrine (50–300 μg/min) or dopamine (2–10 μg/kg/min).
Septic shock: Fever, hypotension, and warm extremities from massive vasodilation, usually seen 5–7 days after initial trauma.
Treatment of Traumatic Shock—Control Bleeding!
The goal in the treatment of shock is to restore tissue perfusion and oxygen delivery (dependent on hemoglobin, cardiac output, and oxygenation).
Secure the airway and administer O2 for SaO2 < 92%.
Diagnose and treat tension pneumothorax.
Control obvious bleeding and assess for occult hemorrhage.
Assess circulation and establish IV access.
Consider cardiac tamponade even if no distended neck veins.
Hemorrhagic shock: Initially, any fluid available.
LR: 1,000 mL expands intravascular volume by
6% hetastarch: 500 mL expands intravascular volume by
7.5% hypertonic saline (HTS) results in the same physiologic response with 1/8th the volume of LR or saline. Two infusions of 250 cc can be used. Although this recommendation has been made by the Institute of Medicine (Washington, DC) and two military consensus groups, 7.5% HTS is not commercially available. 3% and 5% HTS can be used instead and are formulary stock items.
Nonhemorrhagic shock: Crystalloid is the fluid of choice.
Within 1 hour, resuscitate to a mean arterial pressure of > 60 mm Hg, a urine output of 0.5 cc/kg/h, and SaO2 of > 92%.
Responders: Casualties with a sustained response to fluids probably have had significant blood loss but have stopped bleeding. However, they may still require definitive surgery.
Transient and nonresponders are continuing to bleed. They need immediate surgical intervention.
Start blood transfusion as soon as possible.
For nonresponders, fluids may be given to keep the patient alive, but one should not attempt to restore pressure to normal. Consideration should be taken into account of the futility of the resuscitation depending on the tactical scenario.
Follow controlled resuscitation guidelines presented below.
Exsanguinating hemorrhage is the cause of most preventable deaths during war. Combat casualties in shock should be assumed to have hemorrhagic shock until proven otherwise.
Vasopressors have no role in the initial treatment of hemorrhagic shock.
The ideal fluid for resuscitation is still debated despite decades of research that began during WW I (see chart on next page).
Concept of Controlled (Hypotensive/Limited/Balanced) Resuscitation
Raising the blood pressure with fluid resuscitation may dislodge established clots leading to more blood loss. Prior to establishing definitive hemorrhage control, use controlled resuscitation to achieve and maintain adequate perfusion as demonstrated by at least one of the following prioritized goals:
Regains consciousness (follows commands).
Palpable radial pulse.
SBP ~90 mm Hg.
MAP of ~60 mm Hg.
Controlled resuscitation is NOT a substitute for definitive surgical control. It is an attempt to keep a very sick patient alive until he can get to definitive treatment.
Endpoints of resuscitation.
Following definitive hemorrhage control, more traditional endpoints of resuscitation include
Blood pressure: SBP > 120 mm Hg, MAP > 70 mm Hg.
Urine output: > 0.5 mL/kg/h (approximately 30 mL/h).
Correction of acidosis:
base deficit < 2.
serum lactate < 2.5 mmol/L.
Hypothermia: It is important to maintain normal body temperature. Fluids and patient care areas should be warmed. This is often not possible in the deployed environment. Patients frequently arrive at the facility already hypothermic. Keep patients covered when on litters, radiograph tables, and operating tables. External warmers (such as contained forced warm air devices, eg, Bair Hugger) should be employed in all patient care areas from initial emergency area through operating room and ICU. Hypothermia is much easier to prevent than it is to treat. See further discussion of hypothermia in Chapter 12, Damage Control Surgery.
Blood should be added to the resuscitation of patients who have lost 30%–40% of their blood volume. Blood may also be necessary in patients who have not reached this threshold but have ongoing blood loss. Whole blood has a greater risk for immunologic reactions than packed cells.
Blood products fielded with forward medical units (FST, CSH) are predominantly group O packed red cells and FFP. Upon reaching a stabilization phase of operations, type-specific packed cells and platelets will be supplied through theater specific channels. Storage, shelf-life, and availability of these products are outlined in Table 7-2. Familiarity with transfusion technique, patient-donor unit infusion connections, and walking blood bank connections, is essential and should be practiced routinely. Most serious transfusion reactions are the result of an error at the bedside, not an error in typing and cross-matching (ie, transfusing “the right unit to the wrong patient”).
Table 7-2. Blood Products Available to the Theater.
Field Management of a Transfusion Reaction
Under no circumstances should a life-saving transfusion be withheld because of Rh incompatibility; saving a life takes precedence over Rh immunization.
Prevention: When the supply of group O blood permits, group O Rh negative blood should be reserved for women.
>10 Units of PRBC’s in <24 hours.
Whole body blood volume transfusion in a 24-hour period.
Consequences of massive blood loss.
Decrease of coagulation factors.
Decrease of platelets.
Consequences of massive blood transfusions.
Dilution of coagulation factors.
Dilution of platelets.
Hypocalcaemia (citrate toxicity) associated with rapid transfusions.
For every 10 units of PRBCs give:
4 units of FFP.
1 unit of platelets (6 pack of 1 aphresis unit).
Consider 1 dose of cryoprecipitate (10 single units of Cryo).
What blood to use?
Type specific if at all possible.
O positive (preferred) in males and postreproductive females.
O negative (if available) in females of reproductive age.
If still using O after 8 units, stick with O, even if blood type is determined. Stick with O until the patient’s forward and back typed appropriately.
Which FFP to use?
There is no such thing as emergency release FFP.
Type specific if at all possible.
AB when in doubt.
A as a second choice.
Unless you KNOW that the patient is Type O blood, DO NOT use Type O FFP.
When standard blood component therapy is unavailable, the use of fresh whole blood can be lifesaving. Because whole blood contains clotting factors, it is effective for treating dilutional coagulopathy associated with massive blood loss and fluid resuscitation.
Blood recipient set (bag), indirect Tx Y-type (NSN 6515 01 128 1407).
Stopcock, IV therapy 3 way, with Luer lock (NSN 6515 00 864 8864).
Field conditions increase the risk of bacterial contamination.
Definitive testing of blood for transfusion virus diseases is not available.
“Dog tag” blood typing wrong 2%–11% of the time.
Donor performance may be impaired by donation.
Good for small numbers of patients—large numbers lead to doubling of unit ineffectiveness.
Should not be the “default” answer for standard blood program planning.
Donate only once a month.
Avoid donation at high altitudes.
Even in an emergency, try to get regularly issued blood products.
Women—ideally on supplemental iron before/after donation.
Develop a current prescreened donor roster.
Blood type and Rh.
Nonreactive transfusion transmissible disease tests (if available).
Update prescreening donor roster.
Emergency (no roster in place).
Establish blood types with local testing or previous donor history.
Choose prior blood donors in preference to nondonors because they have been tested for the infectious diseases in the past.
Rely on “dog tags” only as a last resort.
Draw only type “O” universal donors in mass casualty situations to reduce the confusion of handling.
Draw universal or type specific donors in case of single patient incidents. (Type
donors are 46% of the US population.)
Procedure for walking blood bank.
Clean donor’s arm with povidone iodine for at least 1 minute.
Draw the blood from an arm vein into an unexpired, intact commercial blood bag.
The bag has a 600 ml capacity and contains 63 mL of CPD or CPDA-1 anticoagulant.
Draw about 450 mL, a “pint,” so that the bag is almost full.
Draw tubes for typing, cross-matching, and transfusion transmissible disease testing (if available).
Send tubes to a supporting laboratory (if available). Even after-the-fact testing is useful to provide reassurance of safety or explanations of untoward events.
Label the bag clearly with blood type and donor identification information.
The white tile method uses a drop of the donor blood mixed with the recipient serum on a white ceramic tile and is examined in 4 minutes.
If no agglutination occurs, the blood is suitable for transfusion into that recipient. A hand lens may be useful.
Keep at room temperature no longer than 24 hours.
Blood stored warm for more than 24 hours has a significant risk of bacterial growth and clotting factors will be lost. If the blood has been kept at room temperature for less than 8 hours, it can be kept in a refrigerator or on wet ice for up to 3 weeks.
Although RBCs remain viable, platelets may become inactive in whole blood stored cold (1°C–10°C) for greater than 24 hours, losing one of the main benefits of fresh whole blood.
Ensure that anesthetist/anesthesiologist and surgeon are aware that this is an emergency-drawn unit and tell them the history of the unit.
After 24 hours, destroy warm-stored, whole-blood units. (Stateside hospitals would do so after exceeding 10°C for 30 minutes.) They are no longer safe or fresh. You may save cold-stored units until a regular supply of tested blood is reestablished.
Keep a record of donors and patients transfused so they can be tested on return to stateside.
Keep a record of number of units transfused, donor names, and outcome.
Blood collected into sterile containers (eg, suction, chest tube, among others) may be returned to the patient through a blood filter.
Blood from sterile cavities, such as the chest or abdomen without visceral injuries is preferred.
Blood from contaminated abdominal wounds can be used at an increased risk of systemic infection.
Blood may be filtered through sterile gauze as a field expedient method.
Because the definition of shock is inadequate oxygenation at the cellular level, the most ideal fluid would provide volume expansion and oxygen-carrying capacity. For this fluid to be useful in deployed settings it needs to be stable at a variety of temperatures and have a low-risk profile. Hemoglobin based oxygen carrying compounds (HBOCs) currently under investigation may be such fluids. There are HBOCs derived from either bovine or human sources that require no refrigeration, have a shelf life of up to 3 years, are disease free, and require no crossmatching.